Related Experiment Video
Updated: Jun 20, 2026
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
Risk stratification for reoperation outcomes in recurrent or persistent papillary thyroid carcinoma: development and
Zimei Tang1, Anwen Ren1, Gang Tian1
1Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Road, Wuhan, 430022, China.
Backgrounds:
Reoperation is a key therapeutic strategy for recurrent or persistent papillary thyroid carcinoma (PTC), but its outcomes remain highly heterogeneous. Effective early risk stratification is essential to guide clinical decision-making and improve patient prognosis. This study aims to develop and validate interpretable machine learning (ML) models for the early prediction of reoperation response in patients with recurrent or persistent PTC.
Methods:
This retrospective study included 670 patients with PTC who underwent reoperation at Wuhan Union Hospital between January 2012 and January 2024. Multiple ML algorithms, including random forest (RF), were used to construct predictive models. Model performance was evaluated by the area under the receiver operating characteristic curve (AUC), and SHapley Additive exPlanations method were applied to interpret feature contributions.
Results:
Among the twelve ML models developed, the RF model demonstrated the highest predictive accuracy. In the training cohort, the RF model achieved an AUC of 0.923 (95% CI, 0.899-0.947); in the validation cohort, the AUC was 0.865 (95% CI, 0.816-0.914). Thirteen variables were retained in the final model, including age, body mass index, Hashimoto's thyroiditis, total tumor size, primary positive lymph node, intraglandular dissemination, gross extrathyroidal extension, primary radioactive iodine treatment, levels of thyroglobulin, the systemic immune-inflammation index, reoperation interval, reoperative lymph node ratio, and recurrent lesion size.
Conclusions:
This study developed and validated an interpretable ML model capable of accurately predicting reoperation outcomes in patients with recurrent or persistent PTC. The model may assist clinicians in identifying high-risk individuals and tailoring personalized treatment strategies.
Clinical Trial Number:
Not applicable.
